Drug Development

Clinical Trials Market Competition Regulatory Approval Pharmaceutical Research Market Trends Clinical Research Biosimilars Oncology FDA Approval Weight Loss Drugs Alzheimer's Treatment Weight-loss Drugs Larger-Molecule Drugs AI in Drug Discovery Phase 3 Clinical Trials Pediatric Medication Clinical Studies Research and Development Pipeline Expansion HIV Prevention Respiratory Diseases Cancer Therapies Innovative Therapies Regulatory Review Vaccine Development Antiviral Drugs Cancer Treatments Acquisition Strategies Weight Management Gene Therapy Preventive Medicine FDA Approval Process Immuno-Oncology Biopharmaceuticals GLP-1 Candidates Regulatory Agencies Market Entry Strategies Biotechnology Innovation Pipeline Regulatory Affairs Regulatory Approvals Market Launches Innovative Treatments Clinical Trends Pipeline Strategies Cellular Biology Injectable Drugs Oral Medications Drug Screening Combination Therapies FDA Approvals Non-invasive Techniques Antidepressants Cost Analysis New Products Clinical Therapies Obesity Drugs Personalized Medicine

Novo Nordisk’s Oral Wegovy Debuts With Strong Prescriptions as BMO Stays Cautious

BMO maintains a Market Perform rating despite early U.S. demand for the new pill.

Lilly Signs Up to $1.12 Billion Gene-Editing Pact to Tackle Hearing Loss

Insilico Medicine Surges on Hong Kong Debut After HK$2.3 Billion IPO

Prolynx Raises $70 Million to Advance Ultra-Long-Acting Obesity Drugs

Mirum to Acquire Bluejay Therapeutics in Up to $820 Million Deal for Hepatitis D Drug

Praxis Relutrigine Study Halted Early for Efficacy as FDA Review Meeting Set

Eli Lilly Becomes First Health Care Company Valued at $1 Trillion

Lilly's Rally Deepens as U.S. Access Deal Recasts Outlook for GLP‑1 Drugs

Bristol Myers and J&J Halt Milvexian Heart-Attack Trial After Futility Finding

Pfizer Wins Metsera With $10 Billion Cash‑Plus‑CVR Offer as Novo Withdraws

Novo Nordisk to Acquire Akero for Up to $5.2 Billion to Expand in MASH

Scripps’ AI–Cryo-EM Pipeline Finds Protective Antibodies in Hours

Lilly’s Oral GLP-1 Pill Meets Phase 3 Goals, Shares Rebound

Novel Non-Opioid Analgesic ADRIANA Advances to U.S. Phase II Trials

Sanofi to Acquire Blueprint Medicines for $9.1 Billion, Boosting Its Rare Immunology Pipeline